Pricing Log in Create free account
Friday 6 November 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BBIO Healthcare Biotechnology

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.

Revenue
+192.6%
EPS
+67.5%
Free cash flow
+60.5%
Total debt
+4.21%

Quarter to September 2026, against a year earlier

74.28 0.01 +0.01%
Market cap
$14.5B
P/E
0.0×
Fwd P/E
−27.5×
Dividend yield
—
F-score
3/9
Altman Z
−3.45
Beneish M
8.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BridgeBio Pharma, Inc. (BBIO) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, BridgeBio Pharma, Inc. (BBIO) trades at a EV/Sales of 15.8×. Over the past ten years it has ranged from 0.0× (December 2020) to 1,223× (July 2023); the current reading is higher than 22% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 31.7× 14.40%
FY2024 27.7× (96.72%)
FY2023 845× 2,805.77%
FY2022 29.1× (38.14%)
FY2021 47.0× (72.21%)
FY2020 169× —
FY2019 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 14.1× (36.53%)
Jun 2026 22.1× (16.89%)
Mar 2026 26.6× (15.95%)
Dec 2025 31.7× 0.39%
23 more quarters

Against its own ten years

Low 0.0× High 1,223×
Ten-year median 30.5×
Current reading's percentile 2

EV/Sales against peers

Company EV/Sales
JAZZ Jazz Pharmaceuticals PLC compare 3.8×
BMRN BioMarin Pharmaceutical Inc. compare 3.9×
EXEL Exelixis, Inc. compare 6.5×
HALO Halozyme Therapeutics, Inc. compare 7.8×
TECH Bio-Techne Corp compare 9.2×
ASND Ascendis Pharma A/S compare 13.3×
BBIO BridgeBio Pharma, Inc. 15.8×
KYMR Kymera Therapeutics, Inc. compare 117×
SMMT Summit Therapeutics PLC compare 17,510×
Biotechnology industry median 9.0×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on BBIO